These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 1718486

  • 21. MOPP, ABVD, or both to treat Hodgkin's disease.
    Aisenberg AC.
    N Engl J Med; 1993 Apr 08; 328(14):1045; author reply 1045-6. PubMed ID: 7680765
    [No Abstract] [Full Text] [Related]

  • 22. Aortic dissection in a patient receiving chemotherapy for Hodgkin's disease--a case report.
    Golden MA, Vaughn DJ, Crooks GW, Holland GA, Bavaria JE.
    Angiology; 1997 Dec 08; 48(12):1063-5. PubMed ID: 9404833
    [Abstract] [Full Text] [Related]

  • 23. Nail dystrophy due to dose-intensive chemotherapy.
    Weihrauch MR, von Bergwelt-Baildon MS.
    Int J Hematol; 2009 Jul 08; 90(1):6-7. PubMed ID: 19543953
    [No Abstract] [Full Text] [Related]

  • 24. Treatment of childhood Hodgkin's disease with chemotherapy alone. Experiences from the Royal Children's Hospital, Melbourne.
    Ekert H.
    Cancer Treat Res; 1989 Jul 08; 41():241-6. PubMed ID: 2484293
    [No Abstract] [Full Text] [Related]

  • 25. Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Final Analysis of a Randomized Phase II Study.
    Clin Adv Hematol Oncol; 2016 Feb 08; 14(2 Suppl 1):9-10. PubMed ID: 27007004
    [No Abstract] [Full Text] [Related]

  • 26. [Treating Hodgkin's disease: for whom the more means better?].
    Illés A.
    Magy Onkol; 2004 Feb 08; 48(2):157-61. PubMed ID: 15351812
    [Abstract] [Full Text] [Related]

  • 27. [Fatal Bacillus cereus sepsis and rhabdomyolysis in a patient with Hodgkin's disease].
    Gómez-Herruz P, Gil-Fernández JJ, Guillen H, Arizcorreta A.
    Enferm Infecc Microbiol Clin; 2011 Mar 08; 29(3):232-3. PubMed ID: 21324561
    [No Abstract] [Full Text] [Related]

  • 28. [Results of the treatment of Hodgkin's disease stage III and IV using the ABVD and BACOP programs].
    Leszko B, Słomkowski M, Przybyszewska M, Apel D, Pawelski S.
    Acta Haematol Pol; 1986 Mar 08; 17(3-4):81-90. PubMed ID: 2438894
    [No Abstract] [Full Text] [Related]

  • 29. Use of gonadotropin-releasing hormone agonists in patients with Hodgkin's disease for preservation of ovarian function and reduction of gonadotoxicity related to chemotherapy.
    Castelo-Branco C, Nomdedeu B, Camus A, Mercadal S, Martínez de Osaba MJ, Balasch J.
    Fertil Steril; 2007 Mar 08; 87(3):702-5. PubMed ID: 17173900
    [Abstract] [Full Text] [Related]

  • 30. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group.
    Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, Eich HT, Mueller-Hermelink HK, Kanz L, Greil R, Rank A, Paulus U, Smardova L, Huber C, Dörken B, Nerl C, Krause SW, Mueller RP, Fuchs M, Engert A.
    J Clin Oncol; 2011 Nov 10; 29(32):4234-42. PubMed ID: 21990399
    [Abstract] [Full Text] [Related]

  • 31. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study.
    Hentrich M, Berger M, Wyen C, Siehl J, Rockstroh JK, Müller M, Fätkenheuer G, Seidel E, Nickelsen M, Wolf T, Rieke A, Schürmann D, Schmidmaier R, Planker M, Alt J, Mosthaf F, Engert A, Arasteh K, Hoffmann C.
    J Clin Oncol; 2012 Nov 20; 30(33):4117-23. PubMed ID: 23045592
    [Abstract] [Full Text] [Related]

  • 32. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials.
    Behringer K, Mueller H, Goergen H, Thielen I, Eibl AD, Stumpf V, Wessels C, Wiehlpütz M, Rosenbrock J, Halbsguth T, Reiners KS, Schober T, Renno JH, von Wolff M, van der Ven K, Kuehr M, Fuchs M, Diehl V, Engert A, Borchmann P.
    J Clin Oncol; 2013 Jan 10; 31(2):231-9. PubMed ID: 23150709
    [Abstract] [Full Text] [Related]

  • 33. Treatment-related mortality in patients with advanced-stage hodgkin lymphoma: an analysis of the german hodgkin study group.
    Wongso D, Fuchs M, Plütschow A, Klimm B, Sasse S, Hertenstein B, Maschmeyer G, Vieler T, Dührsen U, Lindemann W, Aulitzky W, Diehl V, Borchmann P, Engert A.
    J Clin Oncol; 2013 Aug 01; 31(22):2819-24. PubMed ID: 23796987
    [Abstract] [Full Text] [Related]

  • 34. Impact of Bleomycin and Vincristine Dose Reductions in Patients With Advanced Hodgkin Lymphoma Treated With BEACOPP: An Analysis of the German Hodgkin Study Group HD12 and HD15 Trials.
    Haverkamp H, Böll B, Eichenauer DA, Sasse S, Fuchs M, Borchmann P, Diehl V, Engert A, von Tresckow B.
    J Clin Oncol; 2015 Aug 01; 33(22):2430-6. PubMed ID: 26101245
    [Abstract] [Full Text] [Related]

  • 35. Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial.
    Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V.
    J Clin Oncol; 2010 May 01; 28(13):2239-45. PubMed ID: 20368566
    [Abstract] [Full Text] [Related]

  • 36. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial.
    Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, Zijlstra J, Král Z, Fuchs M, Hallek M, Kanz L, Döhner H, Dörken B, Engel N, Topp M, Klutmann S, Amthauer H, Bockisch A, Kluge R, Kratochwil C, Schober O, Greil R, Andreesen R, Kneba M, Pfreundschuh M, Stein H, Eich HT, Müller RP, Dietlein M, Borchmann P, Diehl V, German Hodgkin Study Group, Swiss Group for Clinical Cancer Research, Arbeitsgemeinschaft Medikamentöse Tumortherapie.
    Lancet; 2012 May 12; 379(9828):1791-9. PubMed ID: 22480758
    [Abstract] [Full Text] [Related]

  • 37. [Treatment with CEP (CCNU, VP-16 and prednimustine) in Hodgkin's disease resistant to CVPP and ABVD. Results in 21 patients].
    Cervantes F, Reverter JC, Bladé J, Montserrat E, Rozman C.
    Sangre (Barc); 1988 Jun 12; 33(3):184-7. PubMed ID: 2459787
    [No Abstract] [Full Text] [Related]

  • 38. Fertility in males treated for Hodgkins disease with COPP/ABV hybrid.
    Hobbie WL, Ginsberg JP, Ogle SK, Carlson CA, Meadows AT.
    Pediatr Blood Cancer; 2005 Feb 12; 44(2):193-6. PubMed ID: 15390272
    [Abstract] [Full Text] [Related]

  • 39. Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma.
    Gobbi PG, Valentino F, Danova M, Morabito F, Rovati B, Mammi C, Gentile M, Merli F, Stelitano C, Luminari S, Quintana G, Iannitto E, Brugiatelli M, Federico M.
    Oncol Rep; 2009 Apr 12; 21(4):1029-35. PubMed ID: 19288005
    [Abstract] [Full Text] [Related]

  • 40. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
    Niu Y, Shi YK, He XH, Feng FY, Zhou LQ, Gu DZ.
    Zhonghua Zhong Liu Za Zhi; 2008 Aug 12; 30(8):630-4. PubMed ID: 19102946
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.